Lenvatinib (Lenvabuzz)
Lenvabuzz jasgur life sciences
HOW TO ORDER

Please select product you want to buy & quantity from chawlamedicos.com and email to us at chawlamedicos@hotmail.com we will send prices & quotations to you. once you agree to buy , please send your details in following format :

NAME :
HOUSE NO. :
STREET :
COUNTRY :
CITY :
ZIPCODE :
MOBILE :
EMAIL ID. :
PRODUCT NAME :

shipping by EMS, payments by swift transfer to our company bank account , for swift transfer you will need invoice ,when you send complete name & shipping address , we will send invoice soon ,after you do swift transfer send us copy of bank transfer in english language so we can keep your parcel ready , it takes 2-3 days for payments to reflect in our account dispatch after we receive our bank confirmations. Delivery time 09-15 days after dispatch.

Verification

Lenvatinib (Lenvabuzz)

Lenvatinib (Lenvabuzz) Details
Category

Anti Cancer Drugs

Brand

Jasgur Life Sciences

Ingredient

Lenvabuzz

Prescription Required

Yes

Strength Lenvabuzz
Package 120 Tablets
Ask for Price
Verification

Lenvatinib (Lenvabuzz): Unraveling the Marvels of a Revolutionary Cancer Treatment

In the ever-evolving landscape of pharmaceuticals, the spotlight often falls on groundbreaking medications that offer hope and relief to those grappling with challenging health conditions. Lenvitanib, affectionately known as Lenvabuzz, is one such marvel that has garnered attention for its potential to transform the lives of patients battling certain types of cancers. In this comprehensive article, we will delve into the intricacies of Lenvitanib, exploring its description, uses, benefits, potential side effects, and the critical aspect of safety associated with its consumption.

Understanding Lenvatinib (Lenvabuzz)

Lenvatinib, marketed under various trade names, including Lenvabuzz, is an orally administered multi-kinase inhibitor. It was first approved by the U.S. Food and Drug Administration (FDA) in 2015 for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). The drug inhibits multiple receptors involved in tumour angiogenesis and growth, making it a versatile tool in combating various forms of cancer.

Mechanism of Action

Lenvatinib Lenvabuzz exerts its therapeutic effects by targeting multiple receptor tyrosine kinases (RTKs) implicated in tumour growth and angiogenesis. The key targets of Lenvatinib include vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. By inhibiting these receptors, Lenvatinib disrupts the signalling pathways that promote cancer cell proliferation, survival, and the formation of new blood vessels that nourish tumours.

Uses of Lenvitanib (Lenvabuzz)

  • Thyroid Cancer: Lenvitanib has emerged as a promising therapy for advanced or metastatic differentiated thyroid cancer (DTC). It is indicated for patients who have not responded adequately to radioactive iodine (RAI) treatment or have progressed despite prior therapy.
  • Hepatocellular Carcinoma (HCC): Lenvitanib is also employed in the treatment of hepatocellular carcinoma, the most common type of liver cancer. In patients with unresectable HCC, Lenvitanib has demonstrated efficacy in slowing down tumour progression and improving overall survival rates.

Benefits of Lenvitanib (Lenvabuzz)

  • Tumour Growth Inhibition: Lenvitanib exerts its therapeutic effect by inhibiting multiple pathways involved in tumour angiogenesis, thereby suppressing the growth of cancerous cells. This mechanism makes it a valuable asset in the treatment of advanced thyroid cancer and hepatocellular carcinoma.
  • Improved Progression-Free Survival: Clinical trials have shown that Lenvitanib contributes to a significant increase in progression-free survival (PFS) in patients with advanced thyroid cancer and hepatocellular carcinoma. This benefit is crucial in enhancing the quality of life for individuals battling these aggressive cancers.
  • Multikinase Inhibition: As a tyrosine kinase inhibitor, Lenvitanib's ability to target multiple receptor tyrosine kinases sets it apart. This broad-spectrum inhibition enhances its effectiveness in managing diverse cancers, making it a versatile option for oncologists.

Side Effects of Lenvitanib (Lenvabuzz)

 

While Lenvitanib has demonstrated remarkable efficacy, like any medication, it is not without side effects. Patients undergoing Lenvitanib treatment may experience the following adverse reactions:

  • Hypertension: Lenvitanib is associated with an increased risk of high blood pressure. Regular monitoring of blood pressure is essential during treatment, and antihypertensive medications may be prescribed to manage this side effect.
  • Fatigue: Patients may experience fatigue and weakness during Lenvitanib therapy. Adequate rest and proper management of energy levels are crucial to mitigate this common side effect.
  • Diarrhoea: Gastrointestinal symptoms, such as diarrhoea, are reported by some individuals taking Lenvitanib. Anti-diarrheal medications and dietary adjustments may be recommended to alleviate this side effect.
  • Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome): Lenvitanib can cause redness, swelling, and pain on the palms of the hands and soles of the feet, a condition known as hand-foot syndrome. Topical creams and supportive measures can be employed to manage these symptoms.
  • Proteinuria: Some patients may experience an increase in protein levels in the urine (proteinuria). Regular monitoring and appropriate intervention are necessary to address this potential side effect.

Before taking this medicine

Before embarking on a course of Lenvatinib, marketed as Lenvabuzz, it is imperative to ensure that the medication is safe for the individual. The following considerations should be communicated to the treating physician, who can then assess the suitability of Lenvatinib based on the patient's medical history:

  • Individuals with a history of long QT syndrome, either personally or within their family, should disclose this information to their doctor. Long QT syndrome is a cardiac condition characterized by an irregular heart rhythm, and its presence may impact the safety of Lenvatinib use.
  • Patients with a history of heart disease, high blood pressure, heart attack, heart failure, stroke, or blood clots should inform their healthcare provider. These cardiovascular conditions may necessitate careful monitoring during Lenvatinib treatment.
  • Pre-existing headaches or vision problems should be communicated to the doctor. Lenvatinib may have implications for these conditions, and adjustments to the treatment plan may be required.
  • Individuals with a history of bleeding problems should disclose this information. Lenvatinib's impact on blood clotting mechanisms may require special attention in such cases.
  • A history of stomach or intestinal perforation (a hole or tear) should be communicated to the healthcare provider. Such issues may influence the decision to prescribe Lenvatinib.
  • Patients with a seizure disorder should inform their doctor, as Lenvatinib may have implications for this condition.
  • Individuals who have undergone recent surgery or are planning to have surgery or dental procedures should disclose this information. Lenvatinib treatment may require adjustments in such scenarios.
  • Pre-existing kidney or liver disease should be communicated to the treating physician, as these conditions may impact the safety and dosage of Lenvatinib.
  • Lenvatinib has been associated with jaw bone problems, particularly in individuals with cancer, blood cell disorders, pre-existing dental problems, or those treated with steroids, chemotherapy, or radiation. Patients should discuss their risk factors with their doctor.
  • Lenvatinib has the potential to harm an unborn baby. Before initiating treatment, a negative pregnancy test may be required. Effective birth control methods are recommended during Lenvatinib use and for at least 30 days after the last dose. Both men and women should continue using birth control, as the medication can affect fertility in either parent.
  • Breastfeeding is not advised while using Lenvatinib, and individuals should abstain from it for at least one week after the final dose.

It is crucial for patients to openly communicate their medical history and any concerns with their healthcare provider before commencing Lenvatinib. This collaborative approach ensures that the treatment plan is tailored to the individual's specific health circumstances, maximizing the benefits while minimizing potential risks.

Safety of Lenvitanib (Lenvabuzz)

Ensuring the safety of patients undergoing Lenvitanib treatment involves a comprehensive understanding of its potential risks and benefits. The following considerations are vital for the safe administration of Lenvitanib:

  • Regular Monitoring: Continuous monitoring of blood pressure, liver function, and thyroid function is crucial during Lenvitanib therapy. Close supervision by healthcare professionals helps detect and manage potential adverse effects promptly.
  • Individualized Treatment Plans: The decision to prescribe Lenvitanib is based on a careful assessment of each patient's medical history, overall health, and the specific characteristics of their cancer. Individualized treatment plans help optimize outcomes while minimizing potential risks.
  • Patient Education: Educating patients about the possible side effects and the importance of reporting any unusual symptoms promptly is essential. This empowers patients to actively participate in their care and facilitates early intervention if needed.
  • Collaborative Care Approach: Oncologists, nurses, pharmacists, and other healthcare professionals work collaboratively to ensure comprehensive care for patients undergoing Lenvitanib treatment. Regular communication among the healthcare team members enhances the overall safety and efficacy of the therapy.

Conclusion

Lenvitanib, marketed as Lenvabuzz, represents a significant advancement in the field of oncology, offering hope to patients with advanced thyroid cancer and hepatocellular carcinoma. Its ability to inhibit multiple tyrosine kinases involved in tumour angiogenesis has translated into improved progression-free survival and an enhanced quality of life for many individuals.

For the convenient acquisition of this vital medication, generic Lenvitanib (sold under the name Lenvabuzz) tablets are readily available for online purchase through Chawla Medicos. Recognized as a trusted exporter, Chawla Medicos ensures the direct shipment of Lenvitanib to various countries, including the USA, Mexico, Brazil, Europe, South America, and more.

Category

Anti Cancer Drugs

Brand

Jasgur Life Sciences

Ingredient

Lenvabuzz

Strength Lenvabuzz
Package 120 Tablets
Dosage

Printed on Box

Package Type

120 Tablets

Warnings

Before your doctor tends to prescribe you please ensure it is aware of any sort of allergies you have.

  • Your physician should be aware:
  • Of any herbal supplements, you take
  • That you are not pregnant
  • That you do not have any of the liver/ heart/ kidney disorders

Dietary products because lactation in many people who are on a regular dose of hence intake of such products should be avoided.

Search Drugs By Manufacturer
Search Drugs By Generic Name
Quick Contact
  • +91-9999098733
  • info@chawlamedicos.com
  • +91-9999098733
  • +91-9997777201
  • Chawlamedicos
  • Chawlamedicos
Worldwide Shipping

Worldwide Shipping

Money Back Guarantee

Money Back Guarantee

Product Quality

Product Quality

Customer Support

24*7 Customer Support

Best Price Gurantee

Best Price Gurantee

Some FAQs about Lenvatinib (Lenvabuzz)

Related Products to Lenvatinib (Lenvabuzz)